DDIT3 and diffuse large B-cell lymphoma: To date, promising results have been observed with some combinations, including lenalidomide plus rituximab in follicular lymphoma (FL), lenalidomide plus tafasitamab in R/R DLBCL, everolimus plus R‐CHOP in first‐line DLBCL, and the triplet of ibrutinib, lenalidomide, and rituximab in first‐line DLBCL [16, 17, 18, 19].